Dr. Gannon received a PhD in neuroscience from Florida State University in 1994 and conducted her post-doctoral training at Hoffmann-La Roche in the Institute of Molecular Biology (Nutley, NJ) and Mount Sinai School of Medicine in the Department of Physiology and Biophysics (New York, NY). Although experienced in all aspects of drug development, her main areas of expertise are preclinical efficacy, translational research and nonclinical safety. She has worked extensively in the pharmaceutical industry, holding positions at SmithKline Beecham, Eli Lilly and EPIX Pharmaceuticals. Dr. Gannon joined NeuroPhage in October 2009 and oversees preclinical R&D. Her main focus is currently on the development of NPT001 for neurodegenerative diseases such as Alzheimer´s disease and Parkinson´s disease.